-
1
-
-
0013065232
-
Antifolates
-
Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins
-
Messmann RA and Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 139-184, 2001.
-
(2001)
Cancer Chemotherapy and Biotherapy
, pp. 139-184
-
-
Messmann, R.A.1
Allegra, C.J.2
-
2
-
-
0022613399
-
Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen
-
Thyss A, Milano G, Kubar J, Namer M and Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256-258, 1986.
-
(1986)
Lancet
, vol.1
, pp. 256-258
-
-
Thyss, A.1
Milano, G.2
Kubar, J.3
Namer, M.4
Schneider, M.5
-
4
-
-
33748065311
-
Pharmacokinetic interaction between methotrexate and piperacillin/ tazobactam resulting in prolonged toxic concentration of methotrexate
-
Zarychanski R, Wlodarczyk K, Ariano R and Bow E: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentration of methotrexate. J Antimicrob Chemother 58: 228-230, 2006.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 228-230
-
-
Zarychanski, R.1
Wlodarczyk, K.2
Ariano, R.3
Bow, E.4
-
5
-
-
34548103547
-
Species differences in the inhibitory effect of nonsteroidal antiinflammatory drugs on the uptake of methotrexate by human kidney cells
-
Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T and Sugiyama Y: Species differences in the inhibitory effect of nonsteroidal antiinflammatory drugs on the uptake of methotrexate by human kidney cells. J Pharmacol Exp Ther 322: 1162-1170, 2007.
-
(2007)
J Pharmacol Exp Ther
, vol.322
, pp. 1162-1170
-
-
Nozaki, Y.1
Kusuhara, H.2
Kondo, T.3
Iwaki, M.4
Shiroyanagi, Y.5
Nakayama, H.6
Horita, S.7
Nakazawa, H.8
Okano, T.9
Sugiyama, Y.10
-
6
-
-
0036218554
-
Changes in plasma protein binding have little clinical relevance
-
Benet L and Hoerner BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121, 2002.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 115-121
-
-
Benet, L.1
Hoerner, B.A.2
-
8
-
-
0033845494
-
Potential interaction between methotrexate and omeprazole
-
Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L and Giraldez J: Potential interaction between methotrexate and omeprazole. Ann Pharmacother 34: 1024-1027, 2000.
-
(2000)
Ann Pharmacother
, vol.34
, pp. 1024-1027
-
-
Beorlegui, B.1
Aldaz, A.2
Ortega, A.3
Aquerreta, I.4
Sierrasesumega, L.5
Giraldez, J.6
-
9
-
-
0037157552
-
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate
-
Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H and Meyer FP: Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 324: 1497, 2002.
-
(2002)
Br Med J
, vol.324
, pp. 1497
-
-
Tröger, U.1
Stötzel, B.2
Martens-Lobenhoffer, J.3
Gollnick, H.4
Meyer, F.P.5
-
10
-
-
33746871443
-
Determinants of the elimination of methotrexate and 7-hydroxy- methotrexate following high-dose infusional therapy to cancer patients
-
Joerger M, Huitema A DR, Van den Bongard H JGD, Baas P, Schornagel JH, Schellens JHM and Beijnen JH: Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 62: 71-80, 2005.
-
(2005)
Br J Clin Pharmacol
, vol.62
, pp. 71-80
-
-
Joerger, M.1
Huitema, A.D.R.2
Van Den Bongard, H.J.G.D.3
Baas, P.4
Schornagel, J.H.5
Schellens, J.H.M.6
Beijnen, J.H.7
-
11
-
-
46149091491
-
Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report
-
Bauters TGM, Verlooy J, Robays H and Laureys G: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 30: 316-318, 2008.
-
(2008)
Pharm World Sci
, vol.30
, pp. 316-318
-
-
Bauters, T.G.M.1
Verlooy, J.2
Robays, H.3
Laureys, G.4
-
12
-
-
58149127453
-
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
-
Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y and Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67: 44-49, 2009.
-
(2009)
Br J Clin Pharmacol
, vol.67
, pp. 44-49
-
-
Suzuki, K.1
Doki, K.2
Homma, M.3
Tamaki, H.4
Hori, S.5
Ohtani, H.6
Sawada, Y.7
Kohda, Y.8
-
13
-
-
4143142207
-
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions
-
Breedveld P, Zelcer N, Pluim D, Sönmezer Ö, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P and Schellens JHM: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811, 2004.
-
(2004)
Cancer Res
, vol.64
, pp. 5804-5811
-
-
Breedveld, P.1
Zelcer, N.2
Pluim, D.3
Sönmezer, Ö.4
Tibben, M.M.5
Beijnen, J.H.6
Schinkel, A.H.7
Van Tellingen, O.8
Borst, P.9
Schellens, J.H.M.10
-
14
-
-
33745647522
-
Understanding and managing methotrexate nephrotoxicity
-
Widemann BC and Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 11: 694-703, 2006.
-
(2006)
Oncologist
, vol.11
, pp. 694-703
-
-
Widemann, B.C.1
Adamson, P.C.2
-
15
-
-
15244350370
-
Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure
-
Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U and Fleischhack G: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92: 480-487, 2005.
-
(2005)
Br J Cancer
, vol.92
, pp. 480-487
-
-
Buchen, S.1
Ngampolo, D.2
Melton, R.G.3
Hasan, C.4
Zoubek, A.5
Henze, G.6
Bode, U.7
Fleischhack, G.8
-
17
-
-
37549068911
-
The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane
-
Huls M, Brown CDA, Windass AS, Sayer R, van den Heuvel JJMW, Heemskerk S, Russel FGM and Masereeuw R: The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73: 220-225, 2008.
-
(2008)
Kidney Int
, vol.73
, pp. 220-225
-
-
Huls, M.1
Brown, C.D.A.2
Windass, A.S.3
Sayer, R.4
Van Den Heuvel, J.J.M.W.5
Heemskerk, S.6
Russel, F.G.M.7
Masereeuw, R.8
|